The original study aimed to investigate a vasculo-regenerative program in pulmonary endothelium mediated by the PPARγ-p53 transcription factor complex and demonstrated the potential role of a novel p53-based therapeutic strategy for PAH [42]. Here, PPARG is linked to pulmonary arterial hypertension.